Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations

Hematological Oncology

Volumn 30, Issue 3, 2012, Pages 109-114

  Ferrari, Angela ^a   Bussaglia, Elena ^a   Úbeda, Josep ^a   Facchini, Luca ^a   Aventin, Anna ^a   Sierra, Jorge ^a   Nomdedéu, Josep F ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Acute myeloid leukaemia; Acute promyelocytic leukaemia; Immunophenotype; NPM mutation

Indexed keywords

CD135 ANTIGEN; CD15 ANTIGEN; CD2 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; HLA DR ANTIGEN; MICROSOMAL AMINOPEPTIDASE; NUCLEOPHOSMIN; RETINOIC ACID RECEPTOR ALPHA; THROMBOPOIETIN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; CYTOGENETICS; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

ADULT; ANTIGENS, CD; ANTIGENS, CD15; ANTIGENS, CD34; ANTIGENS, NEOPLASM; DIAGNOSIS, DIFFERENTIAL; FLOW CYTOMETRY; FMS-LIKE TYROSINE KINASE 3; FUCOSYLTRANSFERASES; HLA-DR ANTIGENS; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-BCR; RECEPTORS, THROMBOPOIETIN;

EID: 84866298410     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.1011     Document Type: Article

References (40)

1. Orfao A, Chillón MC, Bortoluci AM, et al. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements. Haematologica 1999; 84: 405-412.
2. Paietta E, Goloubeva O, Neuberg D, et al. A surrogate marker profile for PML/RARalpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes. Cytometry B Clin Cytom 2004; 59B: 1-9.
3. Di Noto R, Mirabelli P, Del Vecchio L. Flow cytometry analysis of acute promyelocytic leukemia: the power of 'surface hematology'. Leukemia 2007; 21: 4-8.
4. Cullen MJ, Richards SJ, O'Connor SJ, et al. Rapid diagnosis of acute promyelocytic leukemia (PML): applicability of flow cytometry and PML protein immunofluorescence. Cancer Genet Cytogenet 2004; 148: 176-177.
5. Paietta E. Expression of cell-surface antigens in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003; 16: 369-385.
6. Fenu S, Carmini D, Mancini F, et al. Acute myeloid leukemias M2 potentially misdiagnosed as M3 variant French-American-Britain (FAB) subtype: a transitional form? Leuk Lymphoma 1995; 18(S1): 49-55.
7. Hayden PJ, O'Connell NM, O'Brien DA, et al. The value of autofluorescence as diagnostic feature of acute promyelocytic leukemia. Haematologica 2006; 91: 417-418.
8. Piedras J, López-Karpovitch X, Cárdenas R. Light scatter and immunophenotypic characteristics of blasts cells in typical acute promyelocytic leukemia and its variant. Cytometry 1998; 32: 286-290.
9. Exner M, Thalhammer R, Kapiotis S, et al. The "typical" immunophenotype of acute promyelocytic leukemia (APL-M3): does it prove true for the M3-variant? Cytometry 2000; 42: 106-109.
10. Oelschlägel U, Nowak R, Mohr B, et al. Specificity of immunophenotyping in acute promyelocytic leukemia. Cytometry 2000; 42: 396-397.
11. Tomonaga M, Yoshida Y, Tagawa M, et al. Cytochemistry of acute promyelocytic leukemia (M3): leukemic promyelocytes exhibit heterogeneous patterns in cellular differentiation. Blood 1985; 66: 350-357.
12. McKenna RW, Parkin J, Bloomfield CD, et al. Acute promyelocytic leukemia: a study of 39 cases with identification of hyperbasophilic microgranular variant. Br J Haematol 1982; 50: 201-214.
13. Moon H, Lee S, Huh J, et al. Characteristics of acute myeloid leukemia without HLA-DR expression. Korean J Lab Med 2007; 27: 313-317.
14. Wetzler M, McElwain BK, Stewart CC, et al. HLA-DR antigen-negative acute myeloid leukaemia. Leukemia 2003; 17: 707-715.
15. Syampurnawati M, Tatsumi E, Furata K, et al. HLA-DR-negative AML (M1 and M2): FLT3 mutations (ITD and D835) and cell-surface antigen expression. Leuk Res 2007; 31: 921-929.
16. Paietta E, Gallagher RE, Wiernik PH. Myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute myeloid leukemia potentially misdiagnosed as FAB-M3 acute myeloid leukemia. Blood 1994; 84: 2824-2825.
17. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with normal karyotype. N Engl J Med 2005; 352: 254-266.
18. Falini B, Nicoletti I, Martelli MF, et al. Acute myeloid leukemia carrying cytoplasmic/mutate nucleophosmin (NPMc+AML): biologic and clinical features. Blood 2007; 109: 874-885.
19. Mrozek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prioritized molecular classification? Blood 2007; 109: 431-448.
20. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favourable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106: 3733-3739.
21. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2008.
22. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
23. Syampurnawati M, Tatsumi E, Ardianto B, et al. DR negativity is a distinctive feature of M1/M2 AML cases with NPM1 mutation. Leuk Res 2008; 32: 1141-1143.
24. Chen W, Rassidakis GZ, Li J, et al. High frequency of NPM1 gene mutations in acute myeloid leukemia with prominent nuclear invaginations ("cuplike" nuclei). Blood 2006; 108: 1783-1784.
25. Kussick SJ, Stirewalt DL, Yi HS, et al. A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication. Leukemia 2004; 18: 1591-1598.
26. Oelschlaegel U, Mohr B, Schaich M, et al. HLA-DR(neg) patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia. Cytometry B Clin Cytom 2009; 76: 321-327.
27. Kern W, Haferlach C, Bacher U, et al. Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity. Leukemia 2009; 23: 1361-1364.
28. Nomdedeu J, Bussaglia E, Villamor N, et al. Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment size. Leuk Res 2011; 35: 163-168. On behalf of the Spanish CETLAM.
29. Lee JA, Splidlen J, Boyce K, et al. MIFlowCyt: the minimum information about a flow cytometry experiment. Cytometry 2008; 73A: 926-930.
30. Murray CK, Estey E, Paietta E, et al. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? J Clin Oncol 1999; 17: 293-297.
31. Di Noto R, Lo Pardo C, Schiavone EM, et al. Stem cell factor receptor (c-kit, CD117) is expressed on blasts cells from most immature types of acute myeloid malignancies but is also a characteristic of a subset of acute promyelocytic leukemia. Br J Haematol 1996; 92: 562-564.
32. Schwartz S, Heinecke A, Zimmermann M, et al. Expression of the c-kit receptor (CD117) is a feature of almost all subtypes of the novo acute myeloblastic leukaemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance. Leuk Lymphoma 1999; 34: 85-94.
33. Erber WN, Asbahr H, Rule SA, et al. Unique immunophenotype of acute promyelocytic leukaemia as defined by CD9 and CD68 antibodies. Br J Haematol 1994; 88: 101-104.
34. Solary E, Casasnovas RO, Campos L, et al. Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR-phenotypes with shorter survival. Leukemia 1992; 6: 393-399.
35. Schlenk RF, Döhner K, Kneba M, et al. The genotype NPM1mut/FLT3-ITDneg is highly significant predictive factor for response to therapy with all-trans retinoic acid in acute myeloid leukemia-results from AMLSG trial AMLHD98B. Blood (ASH Annual Meeting Abstracts) 2007; 110: 297.
36. Schlenk RF, Döhner K, Kneba M, et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from AMLSG Trial AML HD98B. Heamatologica 2009; 94: 54-60.
37. Hütter ML, Döhner K, Schmidt-Wolf IGH, et al. Role of etoposide in combination with all-trans retinoic acid in the treatment of elderly patients with acute myeloid leukemia and NPM1 mutation. Blood (ASH Annual Meeting Abstracts) 2008; 112: 559.
38. Martelli MP, Pettirossi V, Manes N, et al. Selective silencing of the NPM1 mutant protein and apoptosis induction upon ATRA in vitro treatment of AML cells carrying NPM1 mutations. Blood 2007; 110: 868 [Abstract].
39. Estey EH. Treatment of acute myeloid leukemia. Haematologica 2009; 94: 10-16.
40. Burnett AK, Hills RK, Green C, et al. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukaemia: overall results and results in genotypic subgroups defined by mutations in NPM, FLT3, and CEBPA. Blood 2010; 115: 948-956.